Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
Journal
-
- Multiple Sclerosis and Related Disorders
-
Multiple Sclerosis and Related Disorders 47 102641-, 2021-01
Elsevier BV
- Tweet
Details 詳細情報について
-
- CRID
- 1364233270890000512
-
- ISSN
- 22110348
-
- Data Source
-
- Crossref